Evidence map›Paper›PMID 38663769›Full record

Observational studyTransplantation and cellular therapy2024

Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITD

Bhavik J Pandya, Linda J Burns, Tao Wang, Bin Xie, Maelys Touya, James Spalding, Alana Block, Gaston Kuperman, Christopher Young

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Transplantation and cellular therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bhavik J PandyaMedical Affairs, Astellas Pharma Inc., Northbrook, Illinois.
Linda J BurnsCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Tao WangCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.
Bin XieMedical Affairs, Astellas Pharma Inc., Northbrook, Illinois.
Maelys TouyaMedical Affairs, Astellas Pharma Inc., Northbrook, Illinois.
James SpaldingMedical Affairs, Astellas Pharma Inc., Northbrook, Illinois. Electronic address: james.spalding@astellas.com.
Alana BlockMedical Affairs, Astellas Pharma Inc., Northbrook, Illinois.
Gaston KupermanMedical Affairs, Astellas Pharma Inc., Northbrook, Illinois.
Christopher YoungMedical Affairs, Astellas Pharma Inc., Northbrook, Illinois.
Astellas Pharma (United States) · USMedical College of Wisconsin · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) is used to treat patients with acute myeloid leukemia (AML) with internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITD

Indexed as

fms-Like Tyrosine Kinase 3Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteTransplantation, HomologousAdultAgedCanadaFemaleHumansMaleMiddle AgedTreatment OutcomeUnited StatesYoung AdultFLT3 protein, humanfms-Like Tyrosine Kinase 3Acute myeloid leukemiaAllogeneic hemopoietic cell transplantationFLT3 inhibitorRelapseSurvival

Identifiers

PMID38663769
PMCPMC11835383
OpenAlexW4395053589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.